KUALA LUMPUR: CIMB Equities Research thinks investors may have overlooked the potential of Hovid’s pharmaceutical business and efforts to register tocotrienols (a type of Vitamin E) as a US FDA-approved drug.
It said on Monday these positives also appear to be eclipsed by losses at its Carotech subsidiary over the past few years. FY6/13 net profit was the best since FY07 while revenue ex-Carotech hit a record high.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
